Contemporary Treatment Strategies for Resectable Melanoma: Is Earlier Immune Checkpoint Blockade Better?

In this downloadable slideset from a live symposium, experts review key data and provide current recommendations on the use of immune checkpoint inhibitor therapy in the neoadjuvant and upfront settings for patients with advanced melanoma.
Rodabe Amaria, MD
Michael Atkins Headshot
Michael B. Atkins, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.04 MB
Released: March 29, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck & Co., Inc.

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Slides from Clinical Care Options (CCO) on histology-agnostic biomarker testing to guide therapy for gastrointestinal cancer

John L. Marshall, MD Released: July 15, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and gastroesophageal cancers

David H. Ilson, MD, PhD Released: July 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue